Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Cash from Investing Activities (2019 - 2025)

Historic Cash from Investing Activities for Madrigal Pharmaceuticals (MDGL) over the last 14 years, with Q3 2025 value amounting to -$207.0 million.

  • Madrigal Pharmaceuticals' Cash from Investing Activities fell 227.53% to -$207.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.2 million, marking a year-over-year increase of 9265.83%. This contributed to the annual value of -$274.4 million for FY2024, which is 4539.8% up from last year.
  • According to the latest figures from Q3 2025, Madrigal Pharmaceuticals' Cash from Investing Activities is -$207.0 million, which was down 227.53% from $47.9 million recorded in Q2 2025.
  • Madrigal Pharmaceuticals' 5-year Cash from Investing Activities high stood at $163.9 million for Q1 2025, and its period low was -$362.1 million during Q4 2023.
  • In the last 5 years, Madrigal Pharmaceuticals' Cash from Investing Activities had a median value of $15.6 million in 2021 and averaged -$30.0 million.
  • As far as peak fluctuations go, Madrigal Pharmaceuticals' Cash from Investing Activities surged by 42603.17% in 2021, and later plummeted by 317165.06% in 2024.
  • Over the past 5 years, Madrigal Pharmaceuticals' Cash from Investing Activities (Quarter) stood at $15.6 million in 2021, then soared by 324.39% to $66.4 million in 2022, then plummeted by 645.47% to -$362.1 million in 2023, then surged by 86.76% to -$47.9 million in 2024, then tumbled by 331.69% to -$207.0 million in 2025.
  • Its Cash from Investing Activities was -$207.0 million in Q3 2025, compared to $47.9 million in Q2 2025 and $163.9 million in Q1 2025.